Exelixis
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1994-01-01
- Employees
- 1.3K
- Market Cap
- $7.3B
- Website
- http://www.exelixis.com
- Introduction
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.
A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 124
- Registration Number
- NCT06630247
- Locations
- 🇺🇸
Exelixis Clinical Site #3, Nashville, Tennessee, United States
🇺🇸Exelixis Clinical SIte #2, Huntersville, North Carolina, United States
🇺🇸Exelixis Clinical Site #1, Austin, Texas, United States
Study of XB010 in Subjects With Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 350
- Registration Number
- NCT06545331
- Locations
- 🇺🇸
Exelixis Clinical Site #4, Duarte, California, United States
🇺🇸Exelixis Clinical Site #3, Huntersville, North Carolina, United States
🇺🇸Exelixis Clinical Site #1, Austin, Texas, United States
Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)
- Conditions
- Interventions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 140
- Registration Number
- NCT06191796
- Locations
- 🇺🇸
Exelixis Site #8, Los Angeles, California, United States
🇺🇸Exelixis Site #9, Miami, Florida, United States
🇺🇸Exelixis Clinical Site #1, Orlando, Florida, United States
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-10-13
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 500
- Registration Number
- NCT06082167
- Locations
- 🇧🇷
Exelixis Clinical Site #68, Passo Fundo, Rio Grande Do Sul, Brazil
🇺🇸Exelixis Clinical Site #19, Chicago, Illinois, United States
🇺🇸Exelixis Clinical Site #62, Des Moines, Iowa, United States
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients With Advanced Solid Tumors
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 377
- Registration Number
- NCT05932862
- Locations
- 🇺🇸
Exelixis Clinical Site 12, Fountain Valley, California, United States
🇺🇸Exelixis Clinical Site 8, Orlando, Florida, United States
🇺🇸Exelixis Clinical Site 10, Kansas City, Missouri, United States
Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 291
- Registration Number
- NCT05678673
- Locations
- 🇺🇸
Exelixis Clinical Site #164, Newport Beach, California, United States
🇺🇸Exelixis Clinical Site #162, San Francisco, California, United States
🇺🇸Exelixis Clinical Site #163, Aurora, Colorado, United States
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 874
- Registration Number
- NCT05425940
- Locations
- 🇺🇸
Exelixis Clinical Site #77, Los Angeles, California, United States
🇺🇸Exelixis Clinical Site #106, Philadelphia, Pennsylvania, United States
🇺🇸Exelixis Clinical Site #103, Pittsburgh, Pennsylvania, United States
Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-01-04
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 1274
- Registration Number
- NCT05176483
- Locations
- 🇺🇸
Exelixis Clinical Site #32, Pittsburgh, Pennsylvania, United States
🇺🇸Exelixis Clinical Site #24, Pittsburgh, Pennsylvania, United States
🇺🇸Exelixis Clinical Site #89, Dallas, Texas, United States
Study of XL114 in Subjects With Non-Hodgkin's Lymphoma
- First Posted Date
- 2021-12-03
- Last Posted Date
- 2023-07-11
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 2
- Registration Number
- NCT05144347
- Locations
- 🇺🇸
Exelixis Clinical Site #1, Indianapolis, Indiana, United States
🇺🇸Exelixis Clinical #4, Pittsburgh, Pennsylvania, United States
🇺🇸Exelixis Clinical Site #2, Spokane, Washington, United States
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
- Conditions
- Interventions
- First Posted Date
- 2021-06-14
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 573
- Registration Number
- NCT04925284
- Locations
- 🇺🇸
Exelixis Clinical Site #29, Cleveland, Ohio, United States
🇺🇸Exelixis Clinical Site #20, Tucson, Arizona, United States
🇺🇸Exelixis Clinical Site#58, Little Rock, Arkansas, United States